FindTrial
Sign In

Ophthalmic Plastic Surgery

Dexmedetomidine sedation in ophthalmic plastic surgery-safety and efficacy.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/03/012898
Enrollment
100
Registered
2018-03-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Dexmedetomidine Sedation: The drug is administered based on the body weight. An initial loading dose of 1ug/kg was given over a period of 10 minutes followed by maintenance infusion of

Sponsors

Giridhar Eye Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients undergoing ophthalmic plastic surgery procedure above the age of 20 years where the surgical time is more than 30 minutes.

Exclusion criteria

Exclusion criteria: (a) Patients below the age of 20 years. (b) previous history of patients who underwent ophthalmic plastic surgery.

Design outcomes

Primary

MeasureTime frame
To assess the safety profile of the drug in various ophthalmic plastic surgery procedures with respect to blood pressure, heart rate and oxygen saturation rate.Timepoint: 12 Months—

Secondary

MeasureTime frame
To study the efficiency of the drug in terms of analgesia and surgeons comfort.Timepoint: 12 Months—

Countries

India

Contacts

Public ContactDr Marian Pauly

Giridhar Eye Institute

drmarian@giridhareye.org8547505855

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026